90% have completed 12-month follow-up in Stayble Therapeutics' ongoing Phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") announces that approximately 90% of all patients in the Company's ongoing Phase IIb study in degenerative disc disease have completed their 12-month follow-up. The study remains of high quality with a low drop-out rate.

With all patients having completed their six-month visit in February 2023, Stayble was able to secure all critical data to evaluate the primary endpoint of the Phase IIb study. Due to the continued low number of dropouts from the study, Stayble has now successfully completed the 12-month follow-up in approximately 90% of the patient population. This means that all critical data from the six-month follow-up and most of the study data have been.

The study continues according to plan and Stayble intends to present top-line data from the study in Q4 2023.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase 1b trial in LDH.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser.